HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Pipeline of novel immunotherapies may offer ‘more nuanced approach’ to cancer treatment
-
- Addition of daratumumab to chemotherapy doubles PFS in transplant-ineligible newly diagnosed myeloma
- HemOnc Today honors inaugural Next Gen Innovators
- Net neutrality repeal may diminish telemedicine access, harm small practices
- Putting the CAR Ts before the horse John Sweetenham, MD, FRCP, FACP
- FDA approves Faslodex in combination with Verzenio for advanced breast cancer
- FDA authorizes IMPACT test to rapidly identify cancer mutations
- FDA grants breakthrough therapy designation to BCMA antibody-drug conjugate for multiple myeloma
- FDA grants fast track designation to gilteritinib for acute myeloid leukemia
-
- Childhood cancer survivors more likely to stay at jobs for health insurance
- Many cancers associated with modifiable risk factors
- Melanoma immunotherapy trials may not capture all toxicity data
- Prevalence of secondary cancers underscores need for trial inclusion
- Acupuncture reduces joint pain during treatment for early-stage breast cancer
- Circulating tumor cells predict risk for late breast cancer recurrence
- Combined score enhances understanding of breast cancer risk
- Exemestane continues to improve DFS, not OS, for early breast cancer
-
- Exemestane plus enzalutamide extends PFS in some women with breast cancer
- Extended bisphosphonate treatment fails to improve breast cancer survival
- Graft failure remains concern following umbilical cord blood transplantation for leukemia
- High-throughput sequencing aids in diagnosis of bleeding, platelet disorders
- Ibrutinib plus venetoclax shows promise for chronic lymphocytic leukemia
- Pembrolizumab combination shows early potential for trastuzumab-resistant breast cancer
- Responses with CAR T-cell therapy appear durable for non-Hodgkin lymphoma
- SRP54 discovered as a novel cause of congenital neutropenia
-
- Trastuzumab fails to improve outcomes for HER-2-low breast cancer
- Is the success of future immunotherapies dependent on biomarkers?